Double-blind, randomised, active placebo-controlled parallel study (n=126) testing two LSD doses (150 µg; second session 150 or 250 µg) versus low-dose active placebo (10 µg) for alcohol use disorder.
This is a randomised, double-blind, active placebo-controlled parallel study in specialised addiction treatment centres in Switzerland evaluating LSD for the treatment of moderate to severe alcohol use disorder.
Participants receive two dosing days (treatment arm: 150 µg then 150 or 250 µg; comparator: 10 µg then 10 µg). The primary outcome is percent heavy drinking days at three months after administration; secondary objectives include neurobiological mechanisms.
Two-dose LSD regimen with possible escalation in second session (150 µg first; second session 150 µg or 250 µg).
Second session 150 µg or 250 µg
Active placebo arm receiving low-dose LSD (10 µg) in both sessions.
10 µg active placebo in both sessions